MD1374G2 - Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică - Google Patents

Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică

Info

Publication number
MD1374G2
MD1374G2 MD96-0296A MD960296A MD1374G2 MD 1374 G2 MD1374 G2 MD 1374G2 MD 960296 A MD960296 A MD 960296A MD 1374 G2 MD1374 G2 MD 1374G2
Authority
MD
Moldova
Prior art keywords
monoclonal
immunostimulatin
antibodies
obtaining
pharmaceutical composition
Prior art date
Application number
MD96-0296A
Other languages
English (en)
Russian (ru)
Other versions
MD1374F2 (ro
Inventor
Britta Hardy
Avraham Novogrodsky
Original Assignee
Mor Research Application Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mor Research Application Ltd filed Critical Mor Research Application Ltd
Publication of MD1374F2 publication Critical patent/MD1374F2/ro
Publication of MD1374G2 publication Critical patent/MD1374G2/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Detergent Compositions (AREA)

Abstract

Invenţia se referă la medicină şi anume la imunoterapie.Esenţa invenţiei constă în aceea că anticorpul monoclonal imunostimulator sau fragmentul lui legând un antigen, careá legându-se cu celulele B limfoblastoide, induce proliferarea şi activarea limfocitelor sângelui periferic, asigură efectul antitumoral. Anticorpul propus se obţine prin imunizarea animalului cu un imunogen selectat din grupul constituit din celule B limfoblastoide, celule B limfoblastoide lizate sau preparate membranoase din ele, dezvoltarea ulterioară a reacţiei imune la animalul imunizat, extragerea limfocitelor B, creşterea, imortalizarea şi selectarea liniilor celulare, care secretează anticorpul revendicat. De asemenea, se declară linia celulară a hibridomului, depozitat în CNCM sub nr. 1-1397. Se propune o metodă de tratare a maladiilor, care include administrarea unei cantităţi eficiente de anticorp monoclonal propus. Se revendică o compoziţie farmaceutică, ce include în calitate de ingredient activ anticorpul monoclonal imunostimulator indicat. În plus, compoziţia farmaceutică poate suplimentar să conţină un agent care sporeşte activitatea limfocitelor citotoxice.Rezultatul este proliferarea şi activarea limfocitelor, asigurând efectul antitumoral.
MD96-0296A 1994-01-31 1995-01-30 Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică MD1374G2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL10850194A IL108501A (en) 1994-01-31 1994-01-31 Antibodies and pharmaceutical compositions containing them
PCT/US1995/001137 WO1995020605A1 (en) 1994-01-31 1995-01-30 Immuno-stimulatory monoclonal antibodies

Publications (2)

Publication Number Publication Date
MD1374F2 MD1374F2 (ro) 1999-12-31
MD1374G2 true MD1374G2 (ro) 2000-09-30

Family

ID=11065761

Family Applications (1)

Application Number Title Priority Date Filing Date
MD96-0296A MD1374G2 (ro) 1994-01-31 1995-01-30 Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică

Country Status (20)

Country Link
US (1) US5897862A (ro)
EP (1) EP0742795B1 (ro)
JP (1) JP3478398B2 (ro)
CN (1) CN1052733C (ro)
AT (1) ATE171461T1 (ro)
AU (1) AU693526B2 (ro)
CA (1) CA2182289C (ro)
DE (1) DE69504955T2 (ro)
DK (1) DK0742795T3 (ro)
EE (1) EE03285B1 (ro)
ES (1) ES2124533T3 (ro)
FI (1) FI963004A (ro)
IL (1) IL108501A (ro)
LT (1) LT4225B (ro)
LV (1) LV11624B (ro)
MD (1) MD1374G2 (ro)
MX (1) MX9603080A (ro)
NO (1) NO317020B1 (ro)
RU (1) RU2155190C2 (ro)
WO (1) WO1995020605A1 (ro)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL129299A0 (en) * 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
IL149820A0 (en) * 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
FI2206517T3 (fi) 2002-07-03 2023-10-19 Ono Pharmaceutical Co Immuunopotentioivia koostumuksia käsittäen anti-PD-L1 -vasta-aineita
DE10311248A1 (de) * 2003-03-14 2004-09-30 Müller-Hermelink, Hans Konrad, Prof. Dr. Humaner monoklonaler Antikörper
WO2006021955A2 (en) * 2004-08-23 2006-03-02 Mor Research Applications Ltd. Use of bat monoclonal antibody for immunotherapy
EP3530736A3 (en) * 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SI1907424T1 (sl) 2005-07-01 2015-12-31 E. R. Squibb & Sons, L.L.C. Humana monoklonska protitelesa proti programiranem smrtnem ligandu 1 (PD-L1)
AU2008266951B2 (en) 2007-06-18 2013-12-12 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor PD-1
PT2242773T (pt) 2008-02-11 2017-09-15 Cure Tech Ltd Anticorpos monoclonais para o tratamento de tumores
WO2013014668A1 (en) 2011-07-24 2013-01-31 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
US9580504B1 (en) 2013-11-07 2017-02-28 Curetech Ltd. Pidilizumab monoclonal antibody therapy following stem cell transplantation
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
EP3925622A1 (en) 2014-09-13 2021-12-22 Novartis AG Combination therapies
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
IL297090A (en) 2015-07-30 2022-12-01 Macrogenics Inc Molecules that bind pd-1 and methods of using them
US10323091B2 (en) 2015-09-01 2019-06-18 Agenus Inc. Anti-PD-1 antibodies and methods of use thereof
EA201890790A1 (ru) 2015-09-29 2018-10-31 Селджин Корпорейшн Связывающие pd-1 белки и способы их применения
MA43186B1 (fr) 2015-11-03 2022-03-31 Janssen Biotech Inc Anticorps se liant spécifiquement à pd-1 et leurs utilisations
TWI758267B (zh) 2015-12-14 2022-03-21 美商宏觀基因股份有限公司 對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
KR102257154B1 (ko) 2016-09-19 2021-05-28 셀진 코포레이션 Pd-1 결합 단백질을 사용하는 면역 질환의 치료 방법
WO2018053401A1 (en) 2016-09-19 2018-03-22 Celgene Corporation Methods of treating vitiligo using pd-1 binding proteins
AU2017373945A1 (en) 2016-12-07 2019-06-20 Agenus Inc. Antibodies and methods of use thereof
GB202107994D0 (en) 2021-06-04 2021-07-21 Kymab Ltd Treatment of cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5182368A (en) * 1986-06-13 1993-01-26 Ledbetter Jeffrey A Ligands and methods for augmenting B-cell proliferation

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
Clark, E. A, and Ledbetter, J.a. Amplification of the immune response by agonistic antibodies, Immunology Today. 1986, vol. 7, №9, p. 267-270; *
Ellenhorn, Joshua D. et al. In vivo administration of an anti-CD3 prevents malignant progressor tumor growth. Science (Washington, D.C.). 1988, vol. 242, p. 569-571; *
Gallinger, Steven et al. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice. Cancer Research. 1990, vol. 50, p. 2476-2480; *
Hardy, Britta et al. A monoclonal antibody to human B lymphoblastoid cells activates human and murine T lymphocytes. Cellular Immunology. 1989, vol. 118, p.22-29 *
Jenkins, Mars K. et al. CD28 delivers a costimulatory signal involved in antigen-specific IL-2 production by human T cells. The Journal of Immunology. 1991, vol.147, №8, p.2461-2466; *
Jung, Gundram et al. Induction of cytotoxicity in human peripheral blood mononuclear cells by monoclonal antibody OKT3. The Journal of Immunology. 1987, vol.139, №2, p. 639-644; *
Ledbetter, Jeffrey A. et al. Antibodies to Tp67 andTp44 augment and sustain proliferation responses of activated T cell. The Journal of Immunology. 1985, vol. 135, №4, p. 2331-2336; *
Meuer, Stefan C. et al. Triggering of the T3-Ti antigen-receptor complex results in clonal T-cell proliferation through an interleukin-2 dependent autocrine pathway. Proc. Natl. Acad. Sci. USA, 1984, vol. 81, p. 1509-1513; *
Moretta Alessandro et al. CD69-mediated pathway of lymphocyte activation: anti- CD69 monoclonal antibodies trigger the cytolytic activity of different lymphoid effector cells with the exception of cytolytic T lymphocytes expressing T cell receptor (/(. J. Exp. Med., 1991, vol. 174, p.1393-1398; *
Townsend, Sarah E. et al. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science (Washington, D.C.). 1993, vol. 259, p.368-370; *
Van Lier, R., et al. Studies on the monocyte dependence of T-cell proliferation induced by monoclonal antibodies directed against region I and II of the CD2 antigen. Immunology, 1989, vol. 67, p. 333-338; *
Van Lier, Rene( A. W. et al. Signals involved in T cell activation. T cell proliferation induced through the synergistic action of anti-CD28 and anti-CD2 monoclonal antibodies Eur. J. Immunol. 1998, vol. 18, p. 167-172; *
Van Wauwe, Jean P.,et al. OKT3: a monoclonal anti-human T lymphocyte antibody and potent mitogenic properties. The Journal of Immunology. 1980, vol. 124, №6, p. 2708-2713; *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3972C2 (ro) * 2009-03-11 2010-07-31 Ион МЕРЕУЦЭ Remediu şi metodă de tratament al stărilor precanceroase

Also Published As

Publication number Publication date
WO1995020605A1 (en) 1995-08-03
CA2182289A1 (en) 1995-08-03
LT96115A (en) 1997-05-26
US5897862A (en) 1999-04-27
CA2182289C (en) 2003-10-21
NO963168L (no) 1996-09-27
NO963168D0 (no) 1996-07-29
IL108501A (en) 1998-10-30
DE69504955D1 (de) 1998-10-29
EE03285B1 (et) 2000-08-15
NO317020B1 (no) 2004-07-26
ES2124533T3 (es) 1999-02-01
JP3478398B2 (ja) 2003-12-15
LV11624A (en) 1996-12-20
ATE171461T1 (de) 1998-10-15
MX9603080A (es) 1998-01-31
DE69504955T2 (de) 1999-05-27
LV11624B (en) 1997-06-20
EP0742795A1 (en) 1996-11-20
CN1145077A (zh) 1997-03-12
FI963004A0 (fi) 1996-07-29
MD1374F2 (ro) 1999-12-31
LT4225B (en) 1997-10-27
CN1052733C (zh) 2000-05-24
JPH09508390A (ja) 1997-08-26
IL108501A0 (en) 1994-05-30
DK0742795T3 (da) 1999-06-14
FI963004A (fi) 1996-09-27
AU693526B2 (en) 1998-07-02
AU1868695A (en) 1995-08-15
EP0742795B1 (en) 1998-09-23
RU2155190C2 (ru) 2000-08-27

Similar Documents

Publication Publication Date Title
MD1374G2 (ro) Anticorpi monoclonali imunostimulatori, procedeu de obţinere a acestora, linii celulare, metodă de tratare a maladiilor şi compoziţie farmaceutică
DE69709632D1 (de) Humanisierte monoklonale anti-cd40 antikörper und fragmente zur hemmung der b-zellaktivierung
HUP0200537A2 (en) Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases
WO2003099196A3 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
HU9203370D0 (en) Humanized chimaeric anti-icam-1 antibodies and method for producing them
NZ508381A (en) Antibodies, antagonists and agonists of the death domain containing receptor 5 (DR5)
IE890720L (en) Improvements relating to antigens
IL140138A0 (en) Specific antibodies of tie-2 ligands
EP1158004A3 (en) Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof
AU3125289A (en) Monoclonal antibodies directed against human tumor necrosis factor - receptor
ATE233102T1 (de) Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
AU2002223462A1 (en) Use of cd28-specific monoclonal antibodies for stimulating blood cells that lackcd28
EP0194851A3 (en) Human tumor therapy
AU3556901A (en) Use of anti-ferritin monoclonal antibodies in the treatment of some cancers
AU2070688A (en) Antigen recognized by mca 16-88
WO1999043815A3 (en) Human monoclonal antibodies capable of oligospecifically recognizing the major tumor-associated gangliosides and methods of use thereof
NO924803L (no) Tumor-relatert monoklonalt antistoff 88bv59
AU4775899A (en) Human monoclonal antibodies against the tumor antigen uk114 and lymphocyte cellsand hybridomas for their production
WO1998023286A3 (en) Immunoconjugates comprising human monoclonal antibodies or fragments thereof for diagnostic and therapy

Legal Events

Date Code Title Description
PD99 Pending application